Vir Biotechnology (VIR) Stock Price

Vir Biotechnology Price

NASDAQ·CLOSED
9.78USD+0.57 (+6.00 %)
Market closed

Over the last 8 years Vir Biotechnology grew revenue by 49.8% annually, reaching 68.56 M USD. For Vir Biotechnology, the net margin of -638.9% is down versus 48.3% a few years ago. The consensus 12-month price target for Vir Biotechnology is 19.38 USD, about 98.2% above where the stock trades today. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 123% above its 52-week low.

Vir Biotechnology stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Vir Biotechnology over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vir Biotechnology stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vir Biotechnology's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Vir Biotechnology Stock Price History
DateVir Biotechnology Price
8/21/20269.78 USD
8/20/20269.21 USD
8/19/20269.60 USD
8/18/20269.41 USD
8/14/20269.24 USD
8/13/20269.00 USD
8/12/20269.00 USD
8/10/20268.94 USD
8/7/20268.82 USD
8/6/20268.77 USD
8/5/20269.11 USD
8/4/20269.19 USD
8/3/20268.90 USD
7/31/20268.66 USD
7/30/20268.90 USD
7/29/20268.65 USD
7/27/20268.81 USD
7/23/20269.34 USD
7/22/20269.35 USD
7/21/20269.42 USD
7/20/20269.23 USD
7/17/20269.43 USD
7/16/20269.40 USD
7/15/20269.61 USD
7/14/20269.49 USD
7/13/20269.68 USD
7/10/20269.96 USD
7/9/202610.34 USD
7/8/202610.31 USD
7/7/202610.25 USD
7/6/202610.14 USD
7/2/202610.04 USD
7/1/20269.56 USD
6/30/202610.19 USD
6/29/202610.30 USD
6/26/202610.03 USD
6/25/20269.88 USD
6/24/20269.95 USD
6/23/202610.16 USD
6/22/20269.48 USD
6/18/20269.07 USD
6/17/20269.18 USD
6/16/20268.57 USD
6/15/20268.76 USD
6/12/20268.82 USD
6/11/20268.51 USD
6/10/20268.47 USD
6/9/20268.51 USD
6/8/20268.45 USD
6/5/20268.84 USD
6/4/20269.22 USD
6/3/20268.72 USD
6/2/20268.78 USD
6/1/20269.25 USD
5/29/20269.68 USD
5/28/20269.24 USD
5/27/20269.20 USD
5/26/20269.48 USD
5/22/20269.18 USD
5/21/20268.87 USD
5/20/20268.89 USD
5/19/20268.53 USD
5/18/20268.77 USD
5/15/20268.79 USD
5/14/20269.09 USD
5/13/20269.33 USD
5/12/20269.40 USD
5/11/20269.29 USD
5/8/20269.12 USD
5/7/20269.27 USD
5/6/202610.29 USD
5/4/202610.18 USD
5/1/202610.00 USD
4/30/202610.22 USD
4/29/202610.08 USD
4/28/202610.28 USD
4/27/202610.64 USD
4/24/202610.37 USD
4/23/202610.35 USD
4/22/202610.67 USD
4/21/202610.83 USD
4/20/202611.09 USD
4/17/202610.75 USD
4/16/202610.33 USD
4/15/202610.46 USD
4/14/202610.05 USD
4/13/20269.31 USD
4/10/20269.50 USD
4/9/20269.83 USD
4/8/20269.52 USD
4/7/20269.17 USD
4/6/20269.06 USD
4/2/20269.06 USD
4/1/20269.02 USD
3/31/20268.96 USD
3/30/20268.46 USD
3/27/20268.40 USD
3/26/20268.96 USD
3/25/20268.99 USD
3/24/20268.57 USD
3/23/20268.84 USD
3/20/20269.10 USD
3/19/20269.38 USD
3/18/20269.32 USD
3/17/20269.48 USD
3/16/20269.68 USD
3/13/20269.26 USD
3/12/20269.48 USD
3/11/20269.82 USD
3/10/20269.88 USD
3/9/20269.80 USD
3/6/20269.55 USD
3/5/20269.10 USD
3/4/20269.56 USD
3/3/20268.91 USD
3/2/20269.34 USD
2/27/20269.09 USD
2/26/20269.32 USD
2/25/202610.00 USD
2/24/20269.49 USD
2/23/20267.43 USD
2/20/20267.56 USD
2/19/20267.82 USD
2/18/20267.83 USD
2/17/20267.50 USD
2/13/20267.47 USD
2/12/20267.71 USD
2/11/20267.42 USD
2/10/20267.51 USD
2/9/20267.28 USD
2/6/20267.19 USD
2/5/20266.92 USD
2/4/20267.50 USD
2/3/20267.68 USD
2/2/20267.71 USD
1/30/20267.44 USD
1/29/20267.78 USD
1/28/20267.57 USD
1/27/20267.69 USD
1/26/20267.45 USD
1/23/20267.56 USD
1/22/20267.40 USD
1/21/20266.94 USD
1/20/20266.00 USD
1/16/20266.06 USD
1/15/20266.20 USD
1/14/20266.82 USD
1/13/20266.31 USD
1/12/20265.92 USD
1/9/20265.85 USD
1/8/20265.95 USD
1/7/20266.16 USD
1/6/20265.96 USD
1/5/20265.79 USD
1/2/20265.94 USD
12/31/20256.03 USD
12/30/20255.84 USD
12/29/20255.98 USD
12/26/20256.00 USD
12/24/20256.11 USD
12/23/20255.99 USD
12/22/20256.01 USD
12/19/20255.76 USD
12/18/20255.93 USD
12/17/20256.14 USD
12/16/20256.48 USD
12/15/20256.72 USD
12/12/20256.69 USD
12/11/20256.63 USD
12/10/20256.55 USD
12/9/20256.66 USD
12/8/20256.58 USD
12/5/20256.50 USD
12/4/20256.78 USD
12/3/20256.27 USD
12/2/20255.63 USD
12/1/20256.07 USD
11/28/20256.42 USD
11/26/20256.39 USD
11/25/20256.44 USD
11/24/20256.12 USD
11/21/20255.68 USD
11/20/20255.56 USD
11/19/20255.44 USD
11/18/20255.50 USD
11/17/20255.49 USD
11/14/20255.63 USD
11/13/20255.47 USD
11/12/20255.71 USD
11/11/20255.71 USD
11/10/20255.37 USD
11/7/20255.13 USD
11/6/20255.12 USD
11/5/20255.40 USD
11/4/20255.25 USD
11/3/20255.60 USD
10/31/20255.96 USD
10/30/20255.93 USD
10/29/20255.91 USD
10/28/20256.43 USD
10/27/20256.19 USD
10/24/20255.98 USD
10/23/20255.78 USD
10/22/20256.12 USD
10/21/20256.27 USD
10/20/20256.27 USD
10/17/20255.78 USD
10/16/20255.80 USD
10/15/20256.07 USD
10/14/20255.72 USD
10/13/20255.86 USD
10/10/20255.80 USD
10/9/20256.04 USD
10/8/20256.05 USD
10/7/20255.66 USD
10/6/20255.59 USD
10/3/20255.73 USD
10/2/20255.66 USD
10/1/20255.70 USD
9/30/20255.71 USD
9/29/20255.63 USD
9/26/20255.49 USD
9/25/20255.18 USD
9/24/20255.26 USD
9/23/20255.17 USD
9/22/20255.27 USD
9/19/20255.18 USD
9/18/20255.18 USD
9/17/20254.80 USD
9/16/20254.86 USD
9/15/20254.79 USD
9/12/20255.00 USD
9/11/20255.23 USD
9/10/20255.13 USD
9/9/20255.24 USD
9/8/20255.19 USD
9/5/20255.27 USD
9/4/20255.14 USD
9/3/20255.51 USD
9/2/20255.00 USD
8/29/20254.94 USD
8/28/20255.04 USD
8/27/20255.23 USD
8/26/20254.44 USD
8/25/20254.38 USD
Access this data via the Eulerpool API
Get Free API Key

Vir Biotechnology Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
86.18 M USD
-684.31 M USD
-615.06 M USD
Jan 1, 2024
74.21 M USD
-552.17 M USD
-521.96 M USD
Jan 1, 2025
68.56 M USD
-479.51 M USD
-437.99 M USD
Jan 1, 2026 (e)
161.89 M USD
-65.77 M USD
-308.95 M USD
Jan 1, 2027 (e)
93.12 M USD
-37.83 M USD
-375.16 M USD
Jan 1, 2028 (e)
123.64 M USD
-50.23 M USD
-287.81 M USD
Jan 1, 2029 (e)
200.94 M USD
-81.63 M USD
-220.80 M USD
Jan 1, 2030 (e)
262.75 M USD
-106.74 M USD
-188.93 M USD

Vir Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 25, 2026, 12:02 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
–0.010.010.081.101.620.090.070.070.160.090.120.200.260.49
–400.00-20.00850.001,340.7947.49-94.67-13.95-8.11136.76-42.2432.2662.6031.0087.02
3,400.00680.00850.0089.4793.9790.9696.5198.65100.00100.00100.00100.00100.00100.00100.00
0.070.070.070.071.031.470.080.070.070.160.090.120.200.260.49
-80.00-118.00-178.00-297.00420.00833.00-684.00-552.00-479.00-65.00-37.00-50.00-81.00-106.00–
-4,000.00-1,180.00-2,225.00-390.7938.3651.58-795.35-745.95-704.41-40.37-39.78-40.65-40.50-40.46–
-69.00-115.00-174.00-298.00528.00515.00-615.00-521.00-437.00-308.00-375.00-287.00-220.00-188.0012.00
–66.6751.3071.26-277.18-2.46-219.42-15.28-16.12-29.5221.75-23.47-23.34-14.55-106.38
440.30109.4030.30119.20133.40134.80134.13136.25138.52138.52138.52138.52138.52138.52138.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Vir Biotechnology generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vir Biotechnology retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vir Biotechnology's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Vir Biotechnology has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vir Biotechnology's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Vir Biotechnology stock margins

The Vir Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vir Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vir Biotechnology.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
93.99 %
38.42 %
48.26 %
Jan 1, 2022
90.95 %
51.56 %
31.92 %
Jan 1, 2023
96.79 %
-794.04 %
-713.69 %
Jan 1, 2024
98.86 %
-744.11 %
-703.40 %
Jan 1, 2025
99.96 %
-699.44 %
-638.87 %
Jan 1, 2026 (e)
99.96 %
-40.63 %
-190.84 %
Jan 1, 2027 (e)
99.96 %
-40.63 %
-402.88 %
Jan 1, 2028 (e)
99.96 %
-40.63 %
-232.79 %

Vir Biotechnology Stock Revenue, EBIT, Earnings per Share

The Vir Biotechnology earnings per share therefore indicates how much revenue Vir Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.21 USD
3.15 USD
3.96 USD
Jan 1, 2022
11.99 USD
6.18 USD
3.83 USD
Jan 1, 2023
0.64 USD
-5.10 USD
-4.59 USD
Jan 1, 2024
0.54 USD
-4.05 USD
-3.83 USD
Jan 1, 2025
0.49 USD
-3.46 USD
-3.16 USD
Jan 1, 2026 (e)
1.01 USD
-0.47 USD
-1.93 USD
Jan 1, 2027 (e)
0.58 USD
-0.27 USD
-2.35 USD
Jan 1, 2028 (e)
0.77 USD
-0.36 USD
-1.80 USD

Vir Biotechnology business model & stock analysis

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration.

Vir Biotechnology SWOT Analysis

Strengths

Vir Biotechnology Inc has several strengths that provide it with a competitive advantage:

  • Strong scientific expertise and research capabilities
  • Partnerships with leading pharmaceutical companies
  • Advanced technology platforms
  • Robust pipeline of innovative drug candidates
  • Experienced management team

Weaknesses

While Vir Biotechnology Inc enjoys various strengths, it also faces certain weaknesses:

  • Limited financial resources
  • Dependence on external partnerships for funding and development
  • Relatively small market presence compared to larger competitors
  • Potential difficulties in obtaining regulatory approvals
  • Inherent risks associated with drug development

Opportunities

Vir Biotechnology Inc can capitalize on the following opportunities:

  • Growing demand for effective treatments for infectious diseases
  • Increasing focus on personalized medicine and precision therapies
  • Expanding global biopharmaceutical market
  • Potential partnerships and collaborations with academic institutions
  • Advancements in technology and data analytics in the healthcare industry

Threats

There are several potential threats that Vir Biotechnology Inc should consider:

  • Rapidly evolving competitive landscape
  • Stringent regulatory requirements and potential delays
  • Possible negative impact of healthcare reforms and policy changes
  • Intellectual property infringement by competitors
  • Adverse events or unexpected side effects during clinical trials

Vir Biotechnology Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Vir Biotechnology Employees
Details
Date
Vir Biotechnology Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Vir Biotechnology Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Vir Biotechnology historical P/E ratio, EBIT multiple, and P/S ratio

Vir Biotechnology annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Vir Biotechnology shares outstanding

The number of shares of Vir Biotechnology was 138.52 M in 2025. This indicates how many shares Vir Biotechnology is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
133.40 M Stocks
Jan 1, 2022
134.80 M Stocks
Jan 1, 2023
134.13 M Stocks
Jan 1, 2024
136.25 M Stocks
Jan 1, 2025
138.52 M Stocks
Jan 1, 2026 (e)
138.52 M Stocks
Jan 1, 2027 (e)
138.52 M Stocks
Jan 1, 2028 (e)
138.52 M Stocks

Current Vir Biotechnology forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
31.03 %
Buy
92.86 % (13)
Hold
7.14 % (1)
Sell
0.00 % (0)
12M Price Target
19.38
Last Price
9.78
Currency
USD
12M Return Potential
98.16 %
LTM Return
0 %

Vir Biotechnology Analyst Rating Actions

DateFirmActionRatingReliability
6/11/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
6/3/2026
Leerink Partners
Leerink Partners
MaintainedOutperform–
3/4/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
2/25/2026
Barclays
Barclays
MaintainedOverweight56
2/24/2026
Needham
Needham
MaintainedBuy70
2/24/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
2/24/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
2/9/2026
Needham
Needham
MaintainedBuy70
12/30/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
9/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Vir Biotechnology Earnings Calls

2025

Vir Biotechnology Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/20260.34USD-218.62 MUSD-2026 Q2
5/5/2026-0.10USD-110.38 MUSD-2026 Q1
2/23/2026-0.49USD-23.41 MUSD-2025 Q4
5/2/2024-1.07USD-14.53 MUSD-2024 Q1
2/21/2024-1.09USD-13.43 MUSD-2023 Q4
8/2/2023-0.72USD-69.53 MUSD-2023 Q2
5/3/2023-0.59USD-84.75 MUSD-2023 Q1
2/22/2023-0.58USD-84.39 MUSD-2022 Q4
11/3/2022-0.22USD-174.02 MUSD-2022 Q3
8/9/20220.11USD-218.61 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Vir Biotechnology stock

57/100
35
Environment
99
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vir Biotechnology shareholder structure

% Name
11.26515%
BLACKROCK, INC.
BLACKROCK, INC.
8.81291%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
8.20991%
SB Investment Advisers (UK) Limited
SB Investment Advisers (UK) Limited
8.08454%
ARCH Venture Partners
ARCH Venture Partners
8.08454%
ARCH VENTURE MANAGEMENT, LLC
ARCH VENTURE MANAGEMENT, LLC
7.83989%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
...

Vir Biotechnology Beneficial Ownership Filings (SEC 13D/G)

Free Float
76.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
23.00%
Venture Partners IX, LLC
Venture Partners IX, LLC
SEC ↗
23.00%
Venture Fund IX Overage, L.P.
Venture Fund IX Overage, L.P.
SEC ↗
20.60%
SVF Victory (Cayman) Limited
SVF Victory (Cayman) Limited
SEC ↗
20.60%
SoftBank Vision Fund (AIV M1) L.P.
SoftBank Vision Fund (AIV M1) L.P.
SEC ↗
10.80%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
10.10%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
9.00%
95-1411037
95-1411037
SEC ↗
8.50%
Robert Nelsen
Robert Nelsen
SEC ↗
8.30%
Keith Crandell
Keith Crandell
SEC ↗
8.10%
Clinton Bybee
Clinton Bybee
SEC ↗

Vir Biotechnology Executives and Management Board

13 members · avg. age 61 · 38 % women

MB

Dr. Marianne De Backer (56)

President, Chief Executive Officer · since 2023

9.26 M USD

Management

ME

Dr. Mark Eisner (61)

Executive Vice President, Chief Medical Officer

2.76 M USD
JO

Mr. Jason O'byrne (56)

Chief Financial Officer, Executive Vice President

1.92 M USD
VV

Ms. Vanina De Verneuil (46)

Executive Vice President, General Counsel, Corporate Secretary

1.67 M USD
MH

Dr. Maninder Hora

Executive Vice President, Chief Technical Operations Officer

–

Board of Directors

RF

Dr. Ramy Farid (60)

Independent Director

446,336.00 USD
NB

Dr. Norbert Bischofberger (69)

Independent Director

445,136.00 USD
VS

Dr. Vicki Sato (76)

Independent Chairman of the Board

295,583.00 USD
SR

Ms. Saira Ramasastry (49)

Independent Director

285,926.00 USD
RM

Mr. Robert More (57)

Independent Director

283,083.00 USD
CS

Dr. C. Elliott Sigal (73)

Independent Director

280,583.00 USD

Frequently asked questions about Vir Biotechnology

Vir Biotechnology Inc's business model is focused on developing novel therapies to combat serious infectious diseases. The company utilizes cutting-edge technologies and a deep understanding of the immune system to develop treatments for viral infections. Vir Biotechnology aims to address unmet medical needs by harnessing the power of antiviral antibodies and other approaches to provide innovative solutions. With a strong pipeline and strategic partnerships, Vir Biotechnology is dedicated to advancing breakthrough therapies to improve global public health.

Vir Biotechnology Inc is primarily active in the biotechnology industry.

Vir Biotechnology Inc has several main competitors in the market. Some of the notable competitors of Vir Biotechnology Inc include Gilead Sciences Inc, Moderna Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the field of biotechnology and pharmaceuticals, specializing in developing innovative therapies, treatments, and vaccines. With their focus on advancing biomedical research and developing breakthrough solutions, the competitive landscape for Vir Biotechnology Inc remains intense. However, Vir Biotechnology Inc strives to stay at the forefront of the industry by leveraging its expertise and partnerships to address global health challenges and deliver value to its stakeholders.

Vir Biotechnology Inc. is a renowned company with an impressive history and background. Founded in 2016, Vir Biotechnology is a clinical-stage immunology company focused on developing therapeutic solutions for severe infectious diseases. The company is committed to utilizing cutting-edge technologies to address global health challenges. Vir Biotechnology has established strategic partnerships with world-leading institutions and has a diverse portfolio of innovative treatments. With its relentless dedication to scientific excellence and unwavering commitment to public health, Vir Biotechnology Inc. has gained significant recognition and continues to be at the forefront of advancing breakthrough treatments for infectious diseases worldwide.

Vir Biotechnology Inc has achieved several significant milestones in its journey. The company successfully completed its initial public offering (IPO) in October 2019, raising substantial capital to support its research and development efforts. Vir Biotechnology has also formed multiple strategic collaborations with renowned pharmaceutical companies, including Gilead Sciences and GlaxoSmithKline, to advance its pipeline of innovative therapies. Furthermore, Vir Biotechnology received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential therapy for hepatitis B virus infection. These accomplishments demonstrate Vir Biotechnology's commitment to progress and innovation in the field of biotechnology.

Vir Biotechnology Inc is primarily present in the United States.

Vir Biotechnology Inc is a leading biotechnology company with a strong focus on innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and a commitment to improving patient health. Vir Biotechnology Inc believes in leveraging cutting-edge technologies to develop novel therapeutic solutions for the most challenging infectious diseases. With a mission to address global health concerns, the company combines its extensive expertise in immunology and infectious diseases to create transformative treatments and preventive measures. Vir Biotechnology Inc's corporate philosophy centers around the belief that every patient deserves access to safe and effective therapies.

Analysts currently set an average price target of 20.74 USD for the Vir Biotechnology stock (median: 19.38 USD), implying +112.1 % versus the latest price. The consensus is based on 14 analyst ratings.

Vir Biotechnology Analyst Price Targets 2026

14 analysts currently rate the Vir Biotechnology stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Vir Biotechnology to generate revenue of 161.89 M USD and earnings per share of -2.23 USD.

Vir Biotechnology Analyst Price Targets 2026

Converted at the current exchange rate, the Vir Biotechnology share trades at 8.37 EUR (9.78 USD).

The Vir Biotechnology share (VIR) is listed on 1 stock exchanges, including: NASDAQ (VIR).

Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions. Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions.

The expected revenue of Vir Biotechnology is 161.89 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vir Biotechnology is -308.95 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vir Biotechnology is currently -4.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vir Biotechnology stock.

The price-to-sales ratio (P/S) of Vir Biotechnology is currently 8.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vir Biotechnology stock.

The Eulerpool Quality Score for Vir Biotechnology is 1/10.

The ISIN of Vir Biotechnology is US92764N1028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Vir Biotechnology is A2PS0P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Vir Biotechnology is VIR. The ticker symbol is used to trade Vir Biotechnology shares on the stock exchange.

Vir Biotechnology paid dividends every year for the past 0 years.

Vir Biotechnology is assigned to the 'Health' sector.

The dividends of Vir Biotechnology are distributed in USD.

All fundamentals and in-depth analysis of Vir Biotechnology

Our stock analysis for Vir Biotechnology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vir Biotechnology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Vir Biotechnology Stock
Vir Biotechnology Revenue→
Vir Biotechnology Stock
Vir Biotechnology Net Income→
Vir Biotechnology Stock
Vir Biotechnology P/E→
Vir Biotechnology Stock
Vir Biotechnology P/S→
Vir Biotechnology Stock
Vir Biotechnology EBIT→
Vir Biotechnology Stock
Vir Biotechnology Dividend→
Vir Biotechnology Stock
Vir Biotechnology Directors Dealings→
Vir Biotechnology Stock
Vir Biotechnology Stocks→
Vir Biotechnology Stock
Vir Biotechnology Market capitalization→
Vir Biotechnology Stock
Vir Biotechnology Debt→
Vir Biotechnology Stock
Vir Biotechnology Liabilities→
Vir Biotechnology Stock
Vir Biotechnology Equity→
Vir Biotechnology Stock
Vir Biotechnology AAQS→
Vir Biotechnology Stock
Vir Biotechnology Employees→
Vir Biotechnology Stock
Vir Biotechnology ROE→
Vir Biotechnology Stock
Vir Biotechnology ROA→
Vir Biotechnology Stock
Vir Biotechnology ROCE→
Vir Biotechnology Stock
Vir Biotechnology News→
Vir Biotechnology Stock
Vir Biotechnology Analyst Price Targets→

Health Stocks

Virax Biolabs GroupVioquest PharmaceuticalsVirbacVineet LaboratoriesViridian TherapeuticsVincerx PharmaViroGates A/SVincent Medical HoldingsVirpax PharmaceuticalsVimta LabsVisgeneerVimian GroupAll Stocks A–Z →